secwatch.observer — SEC 8-K summary
======================================

Issuer:     OS Therapies Inc (OSTX)
CIK:        0001795091
Form:       8-K
Filed at:   2025-07-14T23:59:59+00:00
Accession:  0001213900-25-063479
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OS Therapies closes $4.2M warrant exercise inducement; extends cash runway to 2026
--------------------------------------------------------------------------------

- Raised $4.2M gross from exercise of 3.8M existing warrants at $1.12/share; issued new warrants at $3.00/share.
- Cash runway extended through 2026, beyond Sept 30, 2026 PRV sunset date for rare pediatric diseases.
- Proceeds to support OST-HER2 regulatory efforts for osteosarcoma, advance OS Animal Health, close OST-504 prostate cancer study, and initiate AI-driven ADC modeling.
- CEO Paul Romness highlighted End of Phase 2 meeting with FDA and Scientific Advice Meetings in UK/Europe.
- New warrants exercisable for 5 years at $3.00/share; forced exercise if stock hits 300% of exercise price for 20 consecutive trading days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1795091/000121390025063479/0001213900-25-063479-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1795091/000121390025063479/ea0248754-8k_ostherap.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-063479

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer